In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback